United States Food and Drug Administration (USFDA) has concluded the inspection at synthetic peptide API facility of Auro Peptides, a subsidiary of Aurobindo Pharma. The said inspection conducted from February 12 to February 16, 2024. The inspection was concluded with zero observations.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
